We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.
- Authors
Chi, Kim N; Fleshner, Neil; Chiuri, Vincenzo Emanuele; Bruwaene, Siska Van; Hafron, Jason; McNeel, Douglas G; Porre, Peter De; Maul, Raymond Scott; Daksh, Mahesh; Zhong, Xiaogang; Mason, Gary E; Tutrone, Ronald F
- Abstract
Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations and had progressed on 1 prior line of novel androgen receptor-targeted therapy. Results from the combination of NIRA with abiraterone acetate plus prednisone, which disrupts androgen axis signaling through inhibition of CYP17, showed promising efficacy and a manageable safety profile in this patient population.
- Subjects
UNITED States; THERAPEUTIC use of antineoplastic agents; HOMOGRAFTS; GENETIC mutation; DNA; EPIDERMAL growth factor receptors; ABIRATERONE acetate; METASTASIS; CASTRATION-resistant prostate cancer; CELLULAR signal transduction; CELLS; RESEARCH funding; PREDNISONE; ANDROGEN receptors
- Publication
Oncologist, 2023, Vol 28, Issue 5, pe309
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1093/oncolo/oyad008